163 related articles for article (PubMed ID: 33889297)
21. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
Cobain EF; Wu YM; Vats P; Chugh R; Worden F; Smith DC; Schuetze SM; Zalupski MM; Sahai V; Alva A; Schott AF; Caram MEV; Hayes DF; Stoffel EM; Jacobs MF; Kumar-Sinha C; Cao X; Wang R; Lucas D; Ning Y; Rabban E; Bell J; Camelo-Piragua S; Udager AM; Cieslik M; Lonigro RJ; Kunju LP; Robinson DR; Talpaz M; Chinnaiyan AM
JAMA Oncol; 2021 Apr; 7(4):525-533. PubMed ID: 33630025
[TBL] [Abstract][Full Text] [Related]
22. Analytic and Clinical Validation of a Pan-Cancer NGS Liquid Biopsy Test for the Detection of Copy Number Amplifications, Fusions and Exon Skipping Variants.
Audetat A; Tschida C; Kreston S; Stephen A; D'Alessio B; Bondy M; Jackson L; Mellert H; Givens N; Sathyanarayana UG; Pestano GA
Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328282
[TBL] [Abstract][Full Text] [Related]
23. Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
Takeda M; Takahama T; Sakai K; Shimizu S; Watanabe S; Kawakami H; Tanaka K; Sato C; Hayashi H; Nonagase Y; Yonesaka K; Takegawa N; Okuno T; Yoshida T; Fumita S; Suzuki S; Haratani K; Saigoh K; Ito A; Mitsudomi T; Handa H; Fukuoka K; Nakagawa K; Nishio K
Oncologist; 2021 Apr; 26(4):e588-e596. PubMed ID: 33325566
[TBL] [Abstract][Full Text] [Related]
24. Concordance Study of a 520-Gene Next-Generation Sequencing-Based Genomic Profiling Assay of Tissue and Plasma Samples.
Wang M; Chen X; Dai Y; Wu D; Liu F; Yang Z; Song B; Xie L; Yang L; Zhao W; Zhang C; Shen W; Fan C; Teng C; Zhao X; Gao N; Shang D; Zhao G; Xin T
Mol Diagn Ther; 2022 May; 26(3):309-322. PubMed ID: 35305253
[TBL] [Abstract][Full Text] [Related]
25. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
[TBL] [Abstract][Full Text] [Related]
26. Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country.
Cifuentes C; Lombana M; Vargas H; Laguado P; Ruiz-Patiño A; Rojas L; Navarro U; Vargas C; Ricaurte L; Arrieta O; Zatarain-Barron L; Zapata L; González G; Ortiz C; Bernal L; Restrepo JG; Viola L; Grosso F; Zapata R; Mantilla W; Carranza H; Bustillo I; Llinas N; Duarte R; Rodríguez J; Archila P; Ávila J; Bermúdez M; Gámez T; Sotelo C; Otero J; Forero E; Lema M; Limpias C; Ordóñez-Reyes C; Mejía S; Rolfo C; Rosell R; Cardona AF; ;
Cancer Control; 2023; 30():10732748231175256. PubMed ID: 37148308
[TBL] [Abstract][Full Text] [Related]
27. A Computational Framework for Comprehensive Genomic Profiling in Solid Cancers: The Analytical Performance of a High-Throughput Assay for Small and Copy Number Variants.
Giacò L; Palluzzi F; Guido D; Nero C; Giacomini F; Duranti S; Bria E; Tortora G; Cenci T; Martini M; De Paolis E; Onori ME; De Bonis M; Normanno N; Scambia G; Minucci A
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551638
[TBL] [Abstract][Full Text] [Related]
28. Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection.
Gray PN; Dunlop CL; Elliott AM
Cancers (Basel); 2015 Jul; 7(3):1313-32. PubMed ID: 26193321
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.
Fehniger JE; Berger AA; Juckett L; Elvin J; Levine DA; Zajchowski DA
Gynecol Oncol; 2019 Dec; 155(3):473-482. PubMed ID: 31703812
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
31. Validation of the Oncomine
Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
[TBL] [Abstract][Full Text] [Related]
32. Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology.
Valentini V; Silvestri V; Bucalo A; Conti G; Karimi M; Di Francesco L; Pomati G; Mezi S; Cerbelli B; Pignataro MG; Nicolussi A; Coppa A; D'Amati G; Giannini G; Ottini L
Front Oncol; 2022; 12():1092201. PubMed ID: 36686738
[TBL] [Abstract][Full Text] [Related]
33. Profiling of gene fusion involving targetable genes in Chinese gastric cancer.
Liu ZH; Zhu BW; Shi M; Qu YR; He XJ; Yuan HL; Ma J; Li W; Zhao DD; Liu ZC; Wang BM; Wang CY; Tao HQ; Ma TH
World J Gastrointest Oncol; 2022 Aug; 14(8):1528-1539. PubMed ID: 36160735
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive genomic profiling of malignant phyllodes tumors of the breast.
Nozad S; Sheehan CE; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Schrock AB; Hirshfield KM; Ali N; Ganesan S; Ali SM; Miller VA; Stephens PJ; Ross JS; Chung JH
Breast Cancer Res Treat; 2017 Apr; 162(3):597-602. PubMed ID: 28210881
[TBL] [Abstract][Full Text] [Related]
35. Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
Shaib WL; Zakka K; Staley C; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF
Oncologist; 2020 May; 25(5):414-421. PubMed ID: 31784493
[TBL] [Abstract][Full Text] [Related]
36. Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.
Seed G; Yuan W; Mateo J; Carreira S; Bertan C; Lambros M; Boysen G; Ferraldeschi R; Miranda S; Figueiredo I; Riisnaes R; Crespo M; Rodrigues DN; Talevich E; Robinson DR; Kunju LP; Wu YM; Lonigro R; Sandhu S; Chinnaiyan AM; de Bono JS
Clin Cancer Res; 2017 Oct; 23(20):6070-6077. PubMed ID: 28751446
[No Abstract] [Full Text] [Related]
37. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes.
San Lucas FA; Allenson K; Bernard V; Castillo J; Kim DU; Ellis K; Ehli EA; Davies GE; Petersen JL; Li D; Wolff R; Katz M; Varadhachary G; Wistuba I; Maitra A; Alvarez H
Ann Oncol; 2016 Apr; 27(4):635-41. PubMed ID: 26681674
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
Steeghs EMP; Kroeze LI; Tops BBJ; van Kempen LC; Ter Elst A; Kastner-van Raaij AWM; Hendriks-Cornelissen SJB; Hermsen MJW; Jansen EAM; Nederlof PM; Schuuring E; Ligtenberg MJL; Eijkelenboom A
BMC Cancer; 2020 Apr; 20(1):291. PubMed ID: 32264863
[TBL] [Abstract][Full Text] [Related]
39. Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay.
Pabla S; Andreas J; Lenzo FL; Burgher B; Hagen J; Giamo V; Nesline MK; Wang Y; Gardner M; Conroy JM; Papanicolau-Sengos A; Morrison C; Glenn ST
Oncotarget; 2019 Aug; 10(50):5181-5193. PubMed ID: 31497248
[TBL] [Abstract][Full Text] [Related]
40. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.
Claerhout S; Lehnert S; Vander Borght S; Spans L; Dooms C; Wauters E; Vansteenkiste J; Weynand B; Deraedt K; Bourgain C; Vanden Bempt I
Lung Cancer; 2022 Apr; 166():242-249. PubMed ID: 35378489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
